Research database


61 months (2021)
Principal investigator(s):
Project type:
UE-funded research - H2020 - Excellent Science - ERC
Funding body:
Project identification number:


This project aims to develop a new generation of multifunctional therapeutic and diagnostic (thus theranostics) nanosystems displaying non-immunogenicity, improved cancer treatment, cell imaging, and high safety for the hosting organism. The innovative concept behind this approach relies on a core-shell nanosystem with a therapeutically active core, i.e. a TrojaNanoHorse (TNH), here validated against leukaemia. The injectable TNH have a lipid bilayer shell derived from autologous cancer cell membrane, naturally non-immunogenic. The hemocompatibility, anti-thrombogenicity, and targeting ability with antibody toward malignant blood cells will be proved during this project. Studies will show the nanocrystal core activation by ultrasound, developing toxic reactive oxygen species (ROS) for cancer killing, and its green fluorescence emission. The whole TNH would go beyond the state-of-the-art due to its nature-derived biomimetic shell, absence of drugs, its safety and biodegrading fate, and green and sonoluminescent emissions for diagnosis. This project will also develop novel set-up for ultrasound-based therapy and diagnosis, impacting on future technology, new standardized protocols for nanomaterial safety assessment, and study chemical and biological mechanism of echogenic ROS development and cavitation effects on cancer cell. Achieving the ultimate goal of a multifunctional TNH will require multidisciplinary expertise in chemistry, material science, biology, medicine and engineering, opening new horizons as nanomedicine tools for efficient cancer therapy with strong scientific, technological and socio-economic benefits.





Total cost: € 1,489,219.00
Total contribution: € 1,489,219.00
PoliTo total cost: € 1,489,219.00
PoliTo contribution: € 1,489,219.00